Live
FierceBiotechGSK CEO's 'scientific courage' propels plans for medley of phase 3 trials for Hansoh-partnered ADCEndpoints NewsGSK plans five Phase 3 studies for gynecological cancer ADC from HansohIlluminaIllumina Inc. stock (US4523271090): Is its genomics leadership strong enough for long-term U.S. inve - AD HOC NEWSAgilentTRADE NEWS: Agilent Technologies to Demonstrate Leading-Edge RF/Microwave Design and Test Solutions - YahooThermo FisherIs Thermo Fisher Scientific (TMO) Pricing Look Stretched After Recent Share Price Rebound - simplywall.stIlluminaIs It Time To Reassess Illumina (ILMN) After Its 61.7% One Year Share Price Rebound - Yahoo FinanceThermo FisherWallace Advisory Group Reduces Stake in Thermo Fisher Scientific - National Today10x Genomics Blog10X Genomics Opens with 6.32% Gain, Outperforming S&P 500's 2.51% Increase - Markets MojoAgilentScaling Antibody-Drug Conjugate Characterization with Lab Automation - the-scientist.comAgilentMassachusetts Financial Services Co. MA Raises Stock Position in Agilent Technologies, Inc. $A - MarketBeatEndpoints NewsMore pharma dealmaking; FDA’s proposed budget; Takeda ends partnership; and moreThermo FisherIs It Too Late To Consider Thermo Fisher Scientific (TMO) After Recent Share Price Weakness? - Yahoo Finance
Endpoints News Apr 12, 2026

GSK plans five Phase 3 studies for gynecological cancer ADC from Hansoh

GSK plans five Phase 3 studies for gynecological cancer ADC from Hansoh

Original
Body unavailable. Use the original source.

Directory

59 All